Lida A. Mina

4.9k total citations · 2 hit papers
64 papers, 3.4k citations indexed

About

Lida A. Mina is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Lida A. Mina has authored 64 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 28 papers in Genetics and 26 papers in Molecular Biology. Recurrent topics in Lida A. Mina's work include PARP inhibition in cancer therapy (30 papers), BRCA gene mutations in cancer (27 papers) and Advanced Breast Cancer Therapies (17 papers). Lida A. Mina is often cited by papers focused on PARP inhibition in cancer therapy (30 papers), BRCA gene mutations in cancer (27 papers) and Advanced Breast Cancer Therapies (17 papers). Lida A. Mina collaborates with scholars based in United States, Spain and France. Lida A. Mina's co-authors include Hope S. Rugo, Sara A. Hurvitz, Johannes Ettl, Jennifer K. Litton, Joanne L. Blum, Anthony Gonçalvès, Ruben G.W. Quek, W. Eiermann, Henri Roché and Young‐Hyuck Im and has published in prestigious journals such as New England Journal of Medicine, Cell and Journal of Clinical Oncology.

In The Last Decade

Lida A. Mina

61 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

2018 1.4k citations Jennifer K. Litton, Hope S. Rugo et al. New England Journal of Medicine profile →
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

2020 252 citations Jennifer K. Litton, Sara A. Hurvitz et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lida A. Mina United States	22	2.5k	1.6k	921	841	834	64	3.4k
Alexander Gutin United States	29	1.7k 0.7×	1.9k 1.2×	1.7k 1.8×	1.4k 1.6×	1.2k 1.4×	115	4.9k
Denka Markova United States	8	1.2k 0.5×	633 0.4×	520 0.6×	420 0.5×	485 0.6×	18	1.7k
Rita K. Schmutzler Germany	19	1.4k 0.6×	1.2k 0.7×	242 0.3×	618 0.7×	695 0.8×	65	2.4k
Stefania Tommasi Italy	28	828 0.3×	1.5k 0.9×	383 0.4×	846 1.0×	688 0.8×	139	2.7k
Rebecca Kristeleit United Kingdom	27	1.6k 0.7×	1.4k 0.9×	326 0.4×	400 0.5×	299 0.4×	147	2.9k
Hariharan Easwaran United States	27	833 0.3×	3.1k 2.0×	315 0.3×	844 1.0×	441 0.5×	48	3.9k
Georgeta Fried Israel	17	1.6k 0.7×	702 0.4×	364 0.4×	539 0.6×	502 0.6×	38	2.1k
Niklas Loman Sweden	27	3.4k 1.4×	2.6k 1.6×	734 0.8×	1.7k 2.0×	2.2k 2.6×	52	5.8k
Jennifer M. Specht United States	27	1.1k 0.5×	685 0.4×	475 0.5×	534 0.6×	272 0.3×	106	2.4k
Deborah Toppmeyer United States	26	2.3k 0.9×	1.1k 0.7×	678 0.7×	1.2k 1.5×	355 0.4×	94	3.4k

Countries citing papers authored by Lida A. Mina

Since Specialization

Citations

This map shows the geographic impact of Lida A. Mina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lida A. Mina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lida A. Mina more than expected).

Fields of papers citing papers by Lida A. Mina

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lida A. Mina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lida A. Mina. The network helps show where Lida A. Mina may publish in the future.

Co-authorship network of co-authors of Lida A. Mina

This figure shows the co-authorship network connecting the top 25 collaborators of Lida A. Mina. A scholar is included among the top collaborators of Lida A. Mina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lida A. Mina. Lida A. Mina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harris, Valerie, Amy M. Boddy, Marco Gerlinger, et al.. (2024). Resistance Management for Cancer: Lessons from Farmers. Cancer Research. 84(22). 3715–3727. 4 indexed citations

Patel, Bhavika, Donald W. Northfelt, Karen S. Anderson, et al.. (2024). Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round. Journal of Clinical Oncology. 42(32). 3826–3836. 10 indexed citations

Jahan, Nusrat, Nicholas Boddicker, Karthik V. Giridhar, et al.. (2024). Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic Experience. Clinical Breast Cancer. 25(3). e211–e219.e2.

Austin, Jessica D., Gina L. Mazza, Juliana M. Kling, et al.. (2024). Factors influencing U.S. women’s interest and preferences for breast cancer risk communication: a cross-sectional study from a large tertiary care breast imaging center. BMC Women s Health. 24(1). 359–359. 1 indexed citations

Telli, Melinda L., Jennifer K. Litton, J. Thaddeus Beck, et al.. (2024). Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status. Breast Cancer. 31(5). 886–897. 8 indexed citations

Batalini, Felipe, et al.. (2023). Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches. International Journal of Molecular Sciences. 24(22). 16198–16198. 33 indexed citations

Goetz, Matthew P., et al.. (2023). A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).. Journal of Clinical Oncology. 41(16_suppl). TPS633–TPS633. 1 indexed citations

Turner, Nicholas C., Alexander Laird, Melinda L. Telli, et al.. (2023). Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study. npj Breast Cancer. 9(1). 81–81. 3 indexed citations

Mina, Lida A., et al.. (2022). PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond. Cancers. 14(17). 4332–4332. 31 indexed citations

10.

Papish, Steven W., et al.. (2021). 564TiP A phase Ib dose-escalation study of ZN-c5, an oral selective estrogen receptor degrader (SERD), in combination with abemaciclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer. Annals of Oncology. 32. S618–S619. 12 indexed citations

11.

Litton, Jennifer K., Sara A. Hurvitz, Lida A. Mina, et al.. (2020). Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Annals of Oncology. 31(11). 1526–1535. 252 indexed citations breakdown →

12.

Chinh, Kelly, Ekin Seçinti, Shelley A. Johns, et al.. (2020). Relations of Mindfulness and Illness Acceptance With Psychosocial Functioning in Patients With Metastatic Breast Cancer and Caregivers. Oncology nursing forum. 47(6). 739–752. 9 indexed citations

13.

Turner, Nicholas C., Melinda L. Telli, Hope S. Rugo, et al.. (2018). A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clinical Cancer Research. 25(9). 2717–2724. 88 indexed citations

14.

Litton, Jennifer K., Hope S. Rugo, Johannes Ettl, et al.. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine. 379(8). 753–763. 1401 indexed citations breakdown →

15.

Kundranda, Madappa N., Jiaxin Niu, Boris G. Naraev, et al.. (2018). Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. OncoTargets and Therapy. Volume 11. 7095–7107. 191 indexed citations

16.

Bono, Johann S. de, Ramesh K. Ramanathan, Lida A. Mina, et al.. (2017). Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discovery. 7(6). 620–629. 314 indexed citations

17.

Mina, Lida A., et al.. (2013). A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109. Investigational New Drugs. 31(5). 1307–1310. 22 indexed citations

18.

Mina, Lida A. & George W. Sledge. (2011). Rethinking the metastatic cascade as a therapeutic target. Nature Reviews Clinical Oncology. 8(6). 325–332. 101 indexed citations

19.

Mina, Lida A., Ian E. Krop, Robin Zoň, et al.. (2009). A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. Investigational New Drugs. 27(6). 565–570. 24 indexed citations

20.

Mina, Lida A., Sunil Badve, Joffre Baker, et al.. (2006). Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Research and Treatment. 103(2). 197–208. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact